Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth Factor-β pathways in prostate cancer

Molecular Pharmacology

Volumn 75, Issue 3, 2009, Pages 429-436

  Assinder, Stephen J ^a   Qihan, Dong ^a   Mangs, Helena ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZOYLPYRIDINE THIOSEMICARBAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ARACHIDONIC ACID; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; ICOSANOID; IRON; IRON CHELATING AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN KINASE B; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG TARGETING; HUMAN; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; MALE; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 62149105928     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053066     Document Type: Review

References (123)

1. Assinder SJ and Nicholson HD (2007) Prostate disease: prostate hyperplasia, prostate cancer, and prostatitis, in Male Reproductive Dysfunction: Pathophysiology and Treatment (Kandeel FR, Swerdloff RS, Pryor JL eds) pp 499-518, Informa Healthcare, New York.
2. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, et al. (2003) The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63:1731-1736.
3. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, Commes T, Watabe M, Gross SC, et al. (2004a) Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 23: 5675-5681.
4. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Commes T, Piquemal D, et al. (2004b) PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 64:7655-7660.
5. Becker EM, Lovejoy DB, Greer JM, Watts R, and Richardson DR (2003) Novel aroylhydrazone iron chelators differ in their iron chelation efficacy and antiproliferative activity: Identification of a new class of potential anti-proliferative agents. Br J Pharmacol 138:819-830.
6. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, and Klocker H (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57:57-65.
7. Bohnsack BL and Hirschi KK (2004) Nutrient regulation of cell cycle progression. Annu Rev Nutr 24:433-453.
8. Brenner RR (1974) The oxidative desaturation of unsaturated fatty acids in animals. Mol Cell Biochem 3:41-52.
9. Burr GO and Burr MM (1929) A new deficiency disease produced by rigid exclusion of fat from the diet. J Biol Chem 82:345-367.
10. Buss JL, Torti FM, and Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021-1034.
11. Cangul H (2004) Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 5:27.
12. Cantley LC and Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci US A 96:4240-4245.
13. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, and Wu H (2008) PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 28:3281-3289.
14. Chaudry AA, Wahle KW, McClinton S, and Moffat LE (1994) Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Ini J Cancer 57:176-180.
15. Chen Y, Martinez LA, LaCava M, Coghlan L, and Conti CJ (1998) Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin Dl. Oncogene 16:1913-1920.
16. Chetcuti A, Margan SH, Russell P, Maim S, Millar DS, Clark SJ, Rogers J, Han-delsman DJ, and Dong Q (2001) Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 61:6331-6334.
17. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, and Carethers JM (2007) RAS/ERK modulates TGFbet a-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28:2321-2327.
18. Clark JD, Schievella AR, Nalefski EA, and Lin LL (1995) Cytosolic phospholipase A2. JLipidMediat Cell Signal 12:83-117.
19. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, and Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291-20299.
20. Covey TM, Edes K, and Fitzpatrick FA (2007) Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 26:5784-5792.
21. 2 as targets for anti-cancer drugs. Biochem Pharmacol 74:949-959.
22. Darnell G and Richardson DR (1999) The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94:781-792.
23. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, and Steck PA (1999). Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMACIPTEN. Cancer Res 59:2551-2556.
24. de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, and Chopin D (2003) Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9:1801-1807.
25. Dong Z, Arnold RJ, Yang Y, Park MH, Hrncirova P, Mechref Y, Novotny MV, and Zhang JT (2005) Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol Cell Proteomics 4:993-1001.
26. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, and Fargion S (2008) Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 172:738-747.
27. Dunn LL, Rahmanto YS, and Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol 17:93-100.
28. Elford HL, Freese M, Passamani E, and Morris HP (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245:5228-5233.
29. Emerling BM, Weinberg F, Liu JL, Mak TW, and Chandel NS (2008) PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through FOXOSa. Proc Natl Acad Sci USA 105:2622-2627.
30. Faas FH, Dang AQ, Pollard M, HongXM, FanK Luckert PH, and Schutz M (1996) Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol 156:243-248.
31. Facher EA and Law JC (1998) PTEN and prostate cancer. J Med Genet 35:790.
32. Faurschou A and Gniadecki R (2008) TNF-alpha stimulates Akt by a distinct aPKC-dependent pathway in premalignant keratinocytes. Exp Dermatol 17:992-997.
33. CPI/WAFI by iron-depletion. Blood 110:752-761.
34. Funk CD and FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 50:470-479.
35. Gao N, Zhang Z, Jiang BH, and Shi X (2003) Role of PISK/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310:1124-1132.
36. Ghosh M, Tucker DE, Burchett SA, and Leslie CC (2006) Properties of the group IV\ phospholipase A2 family. Prog Lipid Res 45:487-510.
37. Green DA, Antholine WE, Wong SJ, Richardson DR, and Chitambar CR (2001) Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 7:3574-3579.
38. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenhmd HF, Albaek C, Schrøder H, and Ørum H (2008) ARNA antagonist of hypoxia-inducible factor-1{alpha}, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7:3598-3608.
39. Groot AJ, Gort EH, van der Wall E, van Diest PJ, and Vooijs M (2008) Conditional inactivation of HIF-1 using intrabodies. Cell Oncol 30:397-409.
40. Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, and Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141-6145.
41. Guo Y and Kyprianou N (1998) Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signalling in human prostate cancer cells. Cell Growth Diff 9:185-193.
42. Guo Y and Kyprianou N (1999) Restoration of transforming growth factor β signalling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59:1366-1371.
43. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, and Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403.
44. Hughes-Fulford M, Chen Y, and Tjandrawinata RR (2001) Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22:701-707.
45. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, and Sayyah S (2006) Arachidonic acid activates phosphatidyhnositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res 66:1427-1433.
46. Hussain A and Dawson N (2000) Management of advanced/metastatic prostate cancer: 2000 update. Oncology 14:1677-1688; discussion 1688, 1691-1694.
47. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science 292:464-468.
48. Jaakkola Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by 02-regulated prolyl hydroxylation. Science 292:468-472.
49. Jordan A and Reichard P (1998) Ribonucleotide reductases. Ann Rev Biochem 67:71-98.
50. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583.
51. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, and Richardson DR (2007) Design, synthesis and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thio-semicarbazone series and their 3-nitrobenzoyl analogs as potent anti-tumor agents. J Med Chem 50:3716-3729.
52. Kovacevic Z, Fu D, and Richardson DR (2008) The iron-regulated metastasis suppressor, Ndrg-1: identification of novel tumor cell-specific targets. Biochim, Biophys Acta 1783:1981-1992.
53. Kovacevic Z and Richardson DR (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355-2366.
54. Larrick JW and Cresswell P (1979) Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supratnol Struct 11:579-586.
55. Le NT and Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603:31-46.
56. Le NT and Richardson DR (2004) Iron chelators with high anti-proliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A novel link between iron metabolism and proliferation. Blood 104:2967-2975.
57. Lee HK, Kwak HY, Hur J, Kim IA, Yang JS, Park MW, Yu J, and Jeong S (2007) Beta-catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells. Cancer Res 67:9315-9321.
58. +-dependent phospholipase A2. Am J Physiol Heart Circ Physiol 288:H2306-H2316.
59. Li F and Malik KU (2005b) Angiotensin Il-induced Akt activation through the epidermal growth factor receptor in vascular smooth muscle cells is mediated by phospholipid metabolites derived by activation of phospholipase D. J Pharmacol Exp Ther 312:1043-1054.
60. Li Z, Chen Y, Cao D, Wang Y, Chen G, Zhang S, and Lu J (2006) Glucocorticoid upregulates transforming growth-β type II receptor enhances TGF-β signalling in human prostate cancer PC-3 cells. Endocrinology 147:5259-5267.
61. Liang SX and Richardson DR (2003) The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the trans activation of WAF1. Carcinogenesis 24:1601-1614.
62. Lovejoy DB and Richardson DR (2002) Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood 100:666-676.
63. Maiming BD and Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
64. Marcus AJ, Broekman MJ, and Pinsky DJ (2002) COX inhibitors and thromboregu-lation. NEngl J Med 347:1025-1026.
65. Massagué J, Blain SW, and Lo RS (2000) TGFβ; signalling in growth control, cancer, and heritable disorders. Cell 103:295-309.
66. Mayo LD, Dixon JE, Durden DL, Tonks NK, and Dornner DB (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277: 5484-5489.
67. McMahon S, Charbonneau M, Grandmont S, Richard DE, and Dubois CM (2006) Transforming growth factor β induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 281:24171-24181.
68. Ni Z, Okeley NM, Smart BP, and Gelb MH (2006) Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. J Biol Chem 281:16245-16255.
69. Nie D, Che M, Grignon D, Tang K, and Honn KV (2001) Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 20:195-206.
70. Nie D, Hilhnan GG, Geddes T, Tang K, Pierson C, Grignon DJ, and Honn KV (1998) Platelet type 12-lipoxygenase in a human prostate carcinoma stimulates angio-genesis and tumor growth. Cancer Res 58:4047-4051.
71. 2-α. Int J Biochem Cell Biol doi: 10.1016/j.biocel. 2008.07.017.
72. Nurtjahja-Tjendraputra E, Fu D, Phang JM, and Richardson DR (2007) Iron chelation regulates eyclln Dl expression via the proteasome: a link to iron-deficiency mediated growth suppression. Blood 109:4045-4054.
73. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, and Thelander L (1993) Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 268:26200-26205.
74. Patel MI, Kurek C, and Dong Q (2008a) The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 179:1668-1675.
75. Patel MI, Singh J, Niknami M, Kurek C, Yao M, Lu S, Maclean F, King NJ, Gelb MH, Scott KF, et al. (2008b) Cytosolic phospholipase A2-α: A potential therapeutic target for prostate cancer. Clin Cancer Res 14:8070-8079.
76. Patel MI, Subbaramaiah K, Du B, Chang M, YangP, Newman RA, Cordon-Cardo C, Thaler HT, and Dannenberg AJ (2005) Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11: 1999-2007.
77. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, et al. (2000) Loss of anniexin 1 correlates with early onset of tumori genes is in esophageal and prostate carcinoma. Cancer Res 60:6293-6297.
78. Pidgeon GP, Kandouz M, Meram A, and Honn KV (2002) Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxegenase inhibition in prostate cancer cells. Cancer Res 62:2721-2727.
79. Porkka KP and Visakorpi T (2004) Molecular mechanisms of prostate cancer. Eur Urol 45:683-691.
80. Pruthi RS, Derkaen JE, Moore D, Carson CC, Grigson G, Watkina C, and Wallen E (2006) Phase II trial of celecoxib in pro state-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12:2172-2177.
81. Richardson D, Ponka P, and Baker E (1994) The effect of the iron(III) chelator, desferoxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54:685-689.
82. Richardson DR (2002) Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42:267-281.
83. Richardson DR (2005) Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer and other diseases. Curr Med Chem 12:2711-2729.
84. Richardson DR and Baker E (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim, Biophys Acta 1053:1-12.
85. Richardson DR, Kalinowski DS. Lau S, Jansson PJ, and Lovejoy DB (2008) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumor agents. Biochim Biophys Acta doi: 10.1016/j.bbagen.2008.04. 003.
86. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II. The mechanism of action of hgands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-l-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038.
87. Richardson DR and Ponka P (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331:1-40.
88. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective anti-tumor activity form iron complexes with marked redox activity. J Med Chem 49:6510-6521.
89. Richardson DR, Trail EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
90. Samuels Y and Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77-82.
91. 1 and interleukin 6 and is soluble receptor with prostate cancer progression. Clin Cancer Res 10:1992-1999.
92. Sharrard RM and Maitland NJ (2000) Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer 83:1102-1109.
93. Shi Y and Massagué J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.
94. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, and Kantoff PW (2006) Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24:2723-2728.
95. Song K, Cornelius SC, Reiss M, and Danielpour D (2003) Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-β by phosphati-dylinositol 3-kiiiase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 278:38342- 38351.
96. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, and de Belle I (2008) The transcription factor Egrl regulates the HIF-1 alpha gene during hypoxia. Mol Carcinog doi: 10.1002/mc.20454
97. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, and Mak TW (2001) Regulation of PTEN transcription by p53. Mol Cell 8:317-325.
98. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, and Holmberg L (2002) Quality of life after radical prostatectomy or watchful waiting. NEngl J Med 347:790-796.
99. 2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J Pharmacol Exp Ther 326:59-68.
100. Sutherland R, Delia D, Schneider C, Newman R, Keinshead J, and Greaves M (1981) Ubiquitous cell surface glycoprotein on tumor cells is proliferation-associated receptor for transferring. Proc Natl Acad Sci US A 78:4515-4519.
101. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, and Lee C (1992) Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells. Prostate 21:133-143.
102. Tanji K, Imaizumi T, Matsumiya T, Itaya H, Fujimoto K, Cui X, Toki T, Ito E, Yoshida H, Wakabayashi K, et al. (2001) Desferoxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 1530:227-235.
103. Ten Dijke P, Goumans MJ, Itoh F, and Itoli S (2002) Regulation of cell proliferation by Smad Proteins. J Cell Physiol 191:1-16.
104. Thigpen AE, Gala KM, Guileyardo JM, Molberg KH, McConnell JD, and Russell DW (1996) Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 155:975-981.
105. Tjandrawinata RR, Dahiya R, and Hughes-Fulford M (1997) Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 75:1111-1118.
106. Tredan O, Galmarini CM, Patel K, and Taimock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441-1454.
107. Trowbridge IS and Lopez F (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Nail Acad Sci USA 79:1175-1179.
108. Vignot S, Faivre S, Aguirre D, and Raymond E (2005) inTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537.
109. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, and Wu H (2006) Pten deletion leads to expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480-1485.
110. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, and Heston WD (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87:1456-1462.
111. Wegiel B, Bjartell A, Culig Z, and Persson JL (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin Al to promote prostate cancer cell survival. Int, J Cancer 122:1522-1529.
112. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent anti-tumor activity that overcome resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906.
113. Wilding G (1991) Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. Cancer Surv 11:147-163.
114. Wildroudt ML and Freeman EJ (2006) Regulation of Akt by arachidonic acid and phosphoinositide 3-kinase in angiotensin II-stimulated vascular smooth muscle cells. Biochim Biophys Acta 1761:11-16.
115. Woo KJ, Lee TJ, Park JW, and Kwon TK (2006) Desferoxamine, an iron chelator, enhances HIF-lalpha accumulation via cyclooxygenase-2 signaling pathway. Biochem Biophys Res Commun 343:8-14.
116. Wymann MP and Schneiter R (2008) Lipid signalling in disease. Nat Rev Mol Cell Biol 9:162-176.
117. Yasui H, Ogura A, Asanuma T, Matsuda A, Kashiwakura I, Kuwabara M, and Inanami O (2008) Inhibition of HIF-lalpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer 99:1442-1452.
118. Yoon G, Kim HJ, Yoon YS, Cho H, Lim IK, and Lee JH (2002) Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor betal (TGF-beta l)-mediated p27Kipl expression. Biochem J 366: 613-621.
119. Yu Y, Kovacevic Z, and Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6:1982-1994.
120. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, and Richardson DR (2006) Chelators at the cancer coalface: desferoxamine to triapine and beyond. Clin Cancer Res 12:6876-6883.
121. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective anti-tumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.
122. Zhang P, Tchou-Wong KM, and Costa M (2007) Egr-1 mediates hypoxia-inducible transcription of the NDRG1 gene through an overlapping Egr-l/Spl binding site in the promoter. Cancer Res 67:9125-9133.
123. Zhu ML, Partin JV, Bruckheimer EM, Strup SE, and Kyprianou N (2008) TGF-β signalling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate 68:287-295.